A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status

被引:0
作者
Jenna M. Collins
Beth L. Nordstrom
Kimmie K. McLaurin
Tapashi B. Dalvi
Susan C. McCutcheon
James C. Bennett
Brian R. Murphy
Puneet K. Singhal
Charles McCrea
Reshma Shinde
Josefa M. Briceno
机构
[1] Evidera,
[2] AstraZeneca Pharmaceuticals,undefined
[3] LP,undefined
[4] AstraZeneca,undefined
[5] Merck & Co.,undefined
[6] Inc.,undefined
来源
Oncology and Therapy | 2021年 / 9卷
关键词
CDK4/6 inhibitors; g; mutation status; Metastatic breast cancer; Survival; Treatment patterns;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:575 / 589
页数:14
相关论文
共 112 条
[1]  
Russnes HG(2017)Breast cancer molecular stratification: from intrinsic subtypes to integrative clusters Am J Pathol 187 2152-2162
[2]  
Lingjaerde OC(2014)Estrogen and progesterone receptors in breast cancer Future Oncol 10 2293-2301
[3]  
Borresen-Dale AL(2014)US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status J Natl Cancer Inst 106 dju055-720
[4]  
Caldas C(2014)Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer Breast 23 710-49S
[5]  
Yip CH(2015)Advances in targeted therapy for breast cancer Fed Pract 32 46S-530
[6]  
Rhodes A(2020)Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Lancet Oncol 21 519-579
[7]  
Howlader N(2017)Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib Breast Cancer (Dove Med Press) 9 567-6
[8]  
Altekruse SF(2003)Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science 302 643-1468
[9]  
Li CI(2014)Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes Breast Cancer Res 16 475-3427
[10]  
Chen VW(2016)Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer J Clin Oncol 34 1460-1366